-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
Arctaris Impact Investors Invests $21M of Preferred Equity in Charlotte, NC Multifamily Opportunity Zone Property
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Wi2Wi Reports 35% Revenue Growth to US$2.36M and Returns to Profitability with US$268K Net Income in Q3 2026
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
Gladstone Capital Corporation Earnings Call and Webcast Information
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
RenX Enterprises Reports Record Third Quarter Revenue of $4.49 Million, Up 27.6% Year Over Year
-
Sebring Design Build Wins Best Universal Design in the 2026 KBB Awards for a Franklin Primary Bath
ASTCT’s Leadership Contributes to FDA Decision to Eliminate REMS for BCMA- and CD19-Directed Autologous CAR T Cell Immunotherapies
CHICAGO, IL / ACCESS Newswire / July 1, 2025 / The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for currently approved B-cell maturation antigen (BCMA)- and CD19-directed autologous chimeric antigen receptor (CAR) T cell therapies. The American Society for Transplantation and Cellular Therapy (ASTCT) contributed to this policy change, in part, by a 2023 multidisciplinary workshop hosted by ASTCT's 80/20 Subcommittee of the Committee on Cellular Therapy.
The workshop convened approximately 70 stakeholders-including clinicians from leading academic centers, regulators, accrediting organizations, professional societies, and immune effector cell (IEC) therapy manufacturers-to evaluate whether the field's existing safety and quality workflows could satisfy REMS requirements. The overwhelming consensus: current infrastructure and practices, supported by education and collaboration, provide a robust foundation for the continued safe use of CAR T therapies. Professional society guidelines, central accrediting, and auditing bodies (eg, FACT, NMDP BioTherapiesSM among others), and transparent data repositories (eg, CIBMTR®) can be leveraged to help ensure safety and quality practices in the absence of REMS requirements.
The workshop findings were communicated directly to the FDA during the Cell Therapy Liaison Meeting, presented at multiple professional society meetings and public regulatory forums and published in the Transplantation and Cellular Therapy journal.
The FDA has determined that REMS programs are no longer necessary to ensure the benefits of these CAR T cell immunotherapies outweigh their risks. This decision acknowledges the hematology/oncology community's extensive experience in managing risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
The FDA concluded that the necessary safety information can be effectively conveyed through current product labeling-including boxed warnings-and Medication Guides, eliminating the need for separate REMS protocols that previously imposed operational burdens on treatment centers. In addition, time frames for monitoring following product administration were streamlined to make the clinical process more feasible for patients and families.
"We appreciate the FDA's decision recognizing the strength of our cell therapy community's clinical infrastructure. With elimination of the REMS requirements, we can reduce unnecessary administrative burden while maintaining the highest standards of patient safety. This will ultimately improve access to life-saving therapies" said Frederick L. Locke, MD, Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa FL, and Chair of the ASTCT Committee on Cellular Therapy."
"This announcement emphasizes the power of advocacy and collaboration between the FDA, accrediting bodies, professional societies and clinical sites in the cell therapy field." Sarah Nikiforow, MD, PhD, Cell Therapy Program at Dana-Farber Cancer Institute in Boston MA and cochair of the ASTCT 80/20 subcommittee.
###
About The American Society for Transplantation and Cellular Therapy® (ASTCT®):
The American Society for Transplantation and Cellular Therapy (ASTCT) is an international professional society dedicated to improving the lives of blood and marrow transplant and cellular therapy patients. ASTCT represents more than 3,900 physicians, investigators and other health care professionals from more than 45 countries. We are dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies.
Contact Information
Jayne Kramer
Marketing Manager
[email protected]
202.367.2313
SOURCE: American Society for Transplantation and Cellular Therapy
View the original press release on ACCESS Newswire
W.Nelson--AT